Dear valued user,
Thank you for using Clearpol. Your support has been invaluable to us and we truly appreciate it. We launched Clearpol two years ago and thousands of users like you have joined us in our mission to simplify healthcare compliance. During the pandemic, we put Clearpol out for free as our way of helping, so you could focus on taking care of your residents.
Listen to our origin story here
As we move forward, we are determined to empower you with cutting-edge AI-enabled tools that will make managing compliance effortless. To bring this vision to life we've partnered with UC Berkeley, a leader in public health and AI research. We will also launch a PRO subscription starting March 1st to ensure the sustainability of Clearpol and to continuously improve the platform for all users. After March 1st, many existing, new, and future features will require a PRO subscription.
As a token of appreciation, we will be offering early adopters, students, and other special users the opportunity to be grandfathered in at an incredibly steep discount. Look out for future communications if you fall into that category.
Thank you for your understanding and continued support. We look forward to serving you in the future.
Best regards,
The Clearpol Team
The Comparison for this document will be available soon.
Your account is being upgraded to Pro!
Signup for Clearpol Pro to benefit from the following premium features and more...
$55/month
$45/month
Try Free for 2 Weeks$350/month
$250/month
Try Free for 2 WeeksWe're sorry to hear that! Help us improve our service, please take a moment to tell us why.
Signup for Clearpol Pro to benefit from the following premium features and more...
$55/month
$45/month
Try Free for 2 Weeks$350/month
$250/month
Try Free for 2 WeeksWe're sorry to hear that! Help us improve our service, please take a moment to tell us why.
Signup for Clearpol Pro to benefit from the following premium features and more...
$55/month
$45/month
Try Free for 2 Weeks$350/month
$250/month
Try Free for 2 WeeksWe're sorry to hear that! Help us improve our service, please take a moment to tell us why.
Signup for Clearpol Pro to benefit from the following premium features and more...
$55/month
$45/month
Try Free for 2 Weeks$350/month
$250/month
Try Free for 2 WeeksWe're sorry to hear that! Help us improve our service, please take a moment to tell us why.
The information provided is used to show regulations that are relevant to your region/facility. By using the platform you agree to the terms and conditions.
Clearpol Inc. does not make any guarantees regarding the accuracy of the opinions provided on our platform. Please use your own judgement.
The California Department of Health has issued an All Facilities Letter regarding the ongoing investigation of contamination at the New England Compounding Center's (NECC) facility. The sterility of any injectable drugs, ophthalmic drugs, and cardioplegic solutions produced by NECC is of significant concern. Healthcare providers are recommended to contact patients who received these products and instruct them to seek immediate medical attention if they experience any symptoms. This is a result of a multistate fungal and bacterial meningitis outbreak associated with recalled lots of compounded methylprednisolone acetate. The letter advises facilities to follow up with patients who meet specific criteria, including receiving injectable products from NECC on or after May 21, 2012. This is an ongoing investigation, and information is subject to change daily. Healthcare facilities should visit the CDC or FDA MedWatch websites for the most up-to-date information on this outbreak.
Clearpol Inc. does not make any guarantees regarding the accuracy of the opinions or summaries provided on our platform. Please use your own judgement.
| Task | Deadline | Actions |
|---|
Click below to print the document in a new window. When finished, you can return to this tab to continue.
Print PDF
Copy Document Link
Please enter a Name.
Please enter a valid email address.
Please enter a first name.
Please enter a last name.
Please enter a valid email address.
